Avient (AVNT) Q4 2025 earnings summary

Executive summary

• Full-year 2025 sales reached $3,260M, up 0.6% year-over-year, with adjusted EBITDA of $545M, up 3.5%, and adjusted EPS of $2.82, up 6%, driven by innovation and productivity, especially in defense, healthcare, and telecom.

• Q4 2025 sales were $761M, up 1.9% year-over-year, with adjusted EBITDA of $118M, up 7.4%, and adjusted EPS of $0.56, up 14.3%.

• Free cash flow reached $195M in 2025, enabling $150M debt reduction and ending with a net leverage ratio of 2.6x.

• Innovation and productivity initiatives drove double-digit growth in defense, healthcare, and telecom, offsetting weak consumer demand and volatile trade policy.

• No acquisitions or divestitures in the past two years, providing clean financial comparisons.

Financial highlights

• Adjusted EBITDA margin reached a record 16.7% for 2025, up 50 bps from 2024.

• Adjusted EPS grew 6% year-over-year, supported by lower interest expense and FX.

• Adjusted ROIC increased to 8.6% in 2025 from 8.3% in 2024.

• Net leverage improved to 2.6x as of December 31, 2025, after paying down $150M in debt.

• Adjusted free cash flow for 2025 was $195M, up from $156M in 2024.

Outlook and guidance

• 2026 adjusted EBITDA guidance: $555M–$585M (+2% to +7% growth); adjusted EPS: $2.93–$3.17 (+4% to +12% growth); Q1 2026 adjusted EPS guidance: $0.81.

• Free cash flow expected at $200M–$220M in 2026, with $140M in capital expenditures, mainly for defense capacity expansion.

• Macro assumptions include easing interest rates, government policy support, and continued NATO defense spending, but persistent inflation and FX volatility remain risks.

• No M&A planned for 2026; focus remains on debt reduction and organic growth.

• Productivity initiatives and cost controls to continue supporting margin expansion.